Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 7Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Vascular Malformations 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Phase IB 1Nevus 1Neoplasms, Plasma Cell 1Lymphoma 1Lymphangioma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hemangioma 1Hemangioendothelioma 1Hamartoma Syndrome, Multiple 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Bone Neoplasms 1Autistic Disorder 1Arteriovenous Malformations 1

Interventions

zanubrutinib 3Rituximab 3Bendamustine Hydrochloride 3ibrutinib 2talquetamab 1pirtobrutinib 1Sra protein, Drosophila 1Specimen Handling 1Sirolimus 1Prednisone 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Everolimus 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Waldenstrom Macroglobulinemia × Everolimus × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡